Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 109.00 | |
5 mg | In stock | $ 239.00 | |
10 mg | In stock | $ 352.00 | |
25 mg | In stock | $ 595.00 | |
50 mg | In stock | $ 848.00 | |
100 mg | In stock | $ 1,170.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 347.00 |
Description | Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study. |
Targets&IC50 | CGRP (human):0.023 nM (Ki) |
Synonyms | Vazegepant HCl |
Molecular Weight | 675.3 |
Formula | C36H47ClN8O3 |
CAS No. | 1414976-20-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (44.43 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vazegepant hydrochloride 1414976-20-7 GPCR/G Protein Neuroscience CGRP Receptor gepant Zavegepant Calcitonin gene-related peptide receptor receptor COVID-19 BHV3500 BHV-3500 BHV 3500 Vazegepant inhibit inflammation migraine intranasal Vazegepant HCl Inhibitor CGRP soluble Vazegepant Hydrochloride inhibitor